$BCDA
BioCardia, Inc.

2020 Q2 Form 10-Q Financial Statement

#000143774920017718 Filed on August 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $27.00K $86.00K
YoY Change -68.6% -64.02%
Cost Of Revenue $0.00 $191.0K
YoY Change -100.0% 41.48%
Gross Profit $27.00K -$105.0K
YoY Change -125.71% -200.96%
Gross Profit Margin 100.0% -122.09%
Selling, General & Admin $1.377M $1.438M
YoY Change -4.24% 8.53%
% of Gross Profit 5100.0%
Research & Development $2.224M $2.219M
YoY Change 0.23% 9.26%
% of Gross Profit 8237.04%
Depreciation & Amortization $22.00K $26.00K
YoY Change -15.38% 18.18%
% of Gross Profit 81.48%
Operating Expenses $3.601M $3.657M
YoY Change -1.53% 8.97%
Operating Profit -$3.574M -$3.762M
YoY Change -5.0% 15.68%
Interest Expense $0.00 $10.00K
YoY Change -100.0% -75.0%
% of Operating Profit
Other Income/Expense, Net $1.000K $12.00K
YoY Change -91.67% -65.71%
Pretax Income -$3.570M -$3.750M
YoY Change -4.8% 16.46%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.573M -$3.750M
YoY Change -4.72% 16.57%
Net Earnings / Revenue -13233.33% -4360.47%
Basic Earnings Per Share
Diluted Earnings Per Share -$463.0K -$773.2K
COMMON SHARES
Basic Shares Outstanding 6.848M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.09M $520.0K
YoY Change 2032.69% -92.39%
Cash & Equivalents $11.09M $517.0K
Short-Term Investments
Other Short-Term Assets $280.0K $430.0K
YoY Change -34.88% 53.57%
Inventory $5.000K
Prepaid Expenses
Receivables $214.0K $204.0K
Other Receivables $520.0K $0.00
Total Short-Term Assets $12.10M $1.152M
YoY Change 950.0% -84.52%
LONG-TERM ASSETS
Property, Plant & Equipment $154.0K $218.0K
YoY Change -29.36% 32.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $54.00K $54.00K
YoY Change 0.0% 0.0%
Total Long-Term Assets $1.032M $1.564M
YoY Change -34.02% 617.43%
TOTAL ASSETS
Total Short-Term Assets $12.10M $1.152M
Total Long-Term Assets $1.032M $1.564M
Total Assets $13.13M $2.716M
YoY Change 383.36% -64.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.525M $1.626M
YoY Change -6.21% 221.98%
Accrued Expenses $132.0K $739.0K
YoY Change -82.14% 310.56%
Deferred Revenue $104.0K $104.0K
YoY Change 0.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $230.0K
YoY Change
Total Short-Term Liabilities $4.551M $4.066M
YoY Change 11.93% 123.53%
LONG-TERM LIABILITIES
Long-Term Debt $280.0K $0.00
YoY Change
Other Long-Term Liabilities $1.010M $890.0K
YoY Change 13.48% 1012.5%
Total Long-Term Liabilities $1.290M $890.0K
YoY Change 44.94% 1012.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.551M $4.066M
Total Long-Term Liabilities $1.290M $890.0K
Total Liabilities $5.837M $4.952M
YoY Change 17.87% 160.22%
SHAREHOLDERS EQUITY
Retained Earnings -$109.2M -$93.78M
YoY Change 16.49% 18.44%
Common Stock $12.00K $44.00K
YoY Change -72.73% 15.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.291M -$2.236M
YoY Change
Total Liabilities & Shareholders Equity $13.13M $2.716M
YoY Change 383.36% -64.55%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$3.573M -$3.750M
YoY Change -4.72% 16.57%
Depreciation, Depletion And Amortization $22.00K $26.00K
YoY Change -15.38% 18.18%
Cash From Operating Activities -$2.350M -$2.250M
YoY Change 4.44% -18.77%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$60.00K
YoY Change -100.0% 50.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$60.00K
YoY Change -100.0% 50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.85M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -2.350M -2.250M
Cash From Investing Activities 0.000 -60.00K
Cash From Financing Activities 10.85M 0.000
Net Change In Cash 8.500M -2.310M
YoY Change -467.97% -17.79%
FREE CASH FLOW
Cash From Operating Activities -$2.350M -$2.250M
Capital Expenditures $0.00 -$60.00K
Free Cash Flow -$2.350M -$2.190M
YoY Change 7.31% -19.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
754000
CY2019Q4 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
519000
CY2020Q2 bcda Accrued Director Compensation Current
AccruedDirectorCompensationCurrent
CY2019Q4 bcda Accrued Director Compensation Current
AccruedDirectorCompensationCurrent
648000
CY2020Q2 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2230000
CY2019Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2561000
CY2020Q2 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
618000
CY2019Q4 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
652000
bcda Issuance Of Restricted Stock Units In Lieu Of Cash Compensation
IssuanceOfRestrictedStockUnitsInLieuOfCashCompensation
613000
bcda Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
bcda Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
CY2020Q2 bcda Grant Liability Current
GrantLiabilityCurrent
622000
CY2019Q4 bcda Grant Liability Current
GrantLiabilityCurrent
630000
bcda Increase Decrease In Current Operating Lease Liability
IncreaseDecreaseInCurrentOperatingLeaseLiability
42000
bcda Increase Decrease In Current Operating Lease Liability
IncreaseDecreaseInCurrentOperatingLeaseLiability
bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
-298000
bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
-256000
bcda Issuance Of Restricted Stock Units In Lieu Of Cash Bonus
IssuanceOfRestrictedStockUnitsInLieuOfCashBonus
391000
bcda Issuance Of Restricted Stock Units In Lieu Of Cash Bonus
IssuanceOfRestrictedStockUnitsInLieuOfCashBonus
bcda Issuance Of Restricted Stock Units In Lieu Of Cash Compensation
IssuanceOfRestrictedStockUnitsInLieuOfCashCompensation
bcda Noncash Compensation Expense
NoncashCompensationExpense
115000
bcda Noncash Compensation Expense
NoncashCompensationExpense
bcda Noncash Interest Expense Accretion To Loan Payable
NoncashInterestExpenseAccretionToLoanPayable
1000
bcda Noncash Interest Expense Accretion To Loan Payable
NoncashInterestExpenseAccretionToLoanPayable
bcda Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
241000
bcda Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
213000
CY2020Q2 bcda Prepaid Expense And Other Current Assets
PrepaidExpenseAndOtherCurrentAssets
277000
CY2019Q4 bcda Prepaid Expense And Other Current Assets
PrepaidExpenseAndOtherCurrentAssets
642000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1160000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
412000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
696000
CY2020Q1 bcda Sharebased Compensation Arrangement By Sharebased Payment Award Remaining Weighted Average Award Vesting Period
SharebasedCompensationArrangementBySharebasedPaymentAwardRemainingWeightedAverageAwardVestingPeriod
P3Y
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1525000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
914000
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
214000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
147000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
132000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
993000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
957000
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
116516000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103433000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
941000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
655000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
690000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
655000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
696000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1596000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1386000
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3569333
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
942088
CY2020Q2 us-gaap Assets
Assets
13128000
CY2019Q4 us-gaap Assets
Assets
7678000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
12096000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
6378000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11086000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5585000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5585000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5358000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11086000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
517000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5501000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4841000
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.36
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.36
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2435807
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2435807
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12425794
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6825183
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12425794
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6825183
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
12000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
104000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
102000
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
191000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
297000
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
3601000
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
3848000
us-gaap Costs And Expenses
CostsAndExpenses
8248000
us-gaap Costs And Expenses
CostsAndExpenses
7752000
CY2020Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
689000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
691000
CY2020Q2 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
us-gaap Depreciation
Depreciation
49000
us-gaap Depreciation
Depreciation
36000
CY2019Q2 us-gaap Depreciation
Depreciation
26000
CY2020Q2 us-gaap Depreciation
Depreciation
22000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
36000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
49000
CY2020Q2 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
519000
CY2019Q4 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.77
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.53
CY2020Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2020Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
157000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
519000
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
610000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
609000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
67000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-70000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
823000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
472000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-85000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-365000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-18000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
964000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
649000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
315000
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4000
CY2020Q2 us-gaap Inventory Net
InventoryNet
CY2019Q4 us-gaap Inventory Net
InventoryNet
4000
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
us-gaap Inventory Write Down
InventoryWriteDown
3000
us-gaap Inventory Write Down
InventoryWriteDown
52000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
78000
CY2020Q2 us-gaap Liabilities
Liabilities
5837000
CY2019Q4 us-gaap Liabilities
Liabilities
5308000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13128000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7678000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4551000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4003000
CY2020Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
281000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10846000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-124000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5336000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4717000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3573000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-3750000
us-gaap Net Income Loss
NetIncomeLoss
-8167000
us-gaap Net Income Loss
NetIncomeLoss
-7415000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4594000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3665000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
16000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
35000
CY2020Q2 us-gaap Notes Payable Current
NotesPayableCurrent
226000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3574000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3762000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8183000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7450000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
150000
us-gaap Operating Lease Expense
OperatingLeaseExpense
301000
CY2019Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
150000
us-gaap Operating Lease Expense
OperatingLeaseExpense
301000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
886000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
570000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
528000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
316000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
614000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
158000
us-gaap Operating Lease Payments
OperatingLeasePayments
315000
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
153000
us-gaap Operating Lease Payments
OperatingLeasePayments
306000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
824000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1065000
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1205
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y182D
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2020Q2 us-gaap Other Operating Income
OtherOperatingIncome
2000
CY2019Q2 us-gaap Other Operating Income
OtherOperatingIncome
13000
us-gaap Other Operating Income
OtherOperatingIncome
18000
us-gaap Other Operating Income
OtherOperatingIncome
36000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1160000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
124000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11500000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
506000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1147000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1138000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
154000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
181000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2224000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2219000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5010000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4385000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109237000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101070000
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
27000
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
86000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
65000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
302000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1505000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1377000
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1438000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3234000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3070000
us-gaap Share Based Compensation
ShareBasedCompensation
1596000
us-gaap Share Based Compensation
ShareBasedCompensation
1386000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
517711
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
24341
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
515036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
300432
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
821464
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1097555
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.99
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.02
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
19.73
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.32
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.15
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
569000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y146D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y219D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y328D
us-gaap Stock Issued1
StockIssued1
148000
us-gaap Stock Issued1
StockIssued1
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10340000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
148000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
2370000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-1283000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
7291000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3792000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
818000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-2236000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(c)</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div> &nbsp; <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> &nbsp; <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, right-of-use assets and related liabilities, incremental borrowing rate, allowances for doubtful accounts and sales returns, derivative instruments, clinical accruals, and inventory valuation.</div></div></div>
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7710577
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4847829
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7636088
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4847746

Files In Submission

Name View Source Status
0001437749-20-017718-index-headers.html Edgar Link pending
0001437749-20-017718-index.html Edgar Link pending
0001437749-20-017718.txt Edgar Link pending
0001437749-20-017718-xbrl.zip Edgar Link pending
bcda-20200630.xml Edgar Link completed
bcda-20200630.xsd Edgar Link pending
bcda-20200630_cal.xml Edgar Link unprocessable
bcda-20200630_def.xml Edgar Link unprocessable
bcda-20200630_lab.xml Edgar Link unprocessable
bcda-20200630_pre.xml Edgar Link unprocessable
bcda20200630_10q.htm Edgar Link pending
ex_198131.htm Edgar Link pending
ex_198132.htm Edgar Link pending
ex_198133.htm Edgar Link pending
ex_198134.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending